Search Results for "meetings"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for meetings. Results 161 to 170 of 172 total matches.

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
. Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). October 16, 2019. Available at: https ...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 |  Show IntroductionHide Introduction

Treatment of Clostridium difficile-Associated Disease (CDAD)

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006  (Issue 1247)
diarrhea (CDAD). 44th Annual Meeting of IDSA in Toronto, Canada, October 12-15, 2006; page 60, abstract ...
The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third generation cephalosporins, clindamycin and fluoroquinolones. The emergence in recent years of a new, more toxic epidemic strain (BI/NAP1), possibly related to widespread use of fluoroquinolones, has caused a marked increase in the incidence and severity of C. difficile-associated disease (CDAD).
Med Lett Drugs Ther. 2006 Nov 6;48(1247):89-90 |  Show IntroductionHide Introduction

Erythropoietin Safety Concerns

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
or radiotherapy. Presented at the 2007 annual meeting of the American Association for Cancer Research, April 14 ...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
Med Lett Drugs Ther. 2007 May 7;49(1260):37-9 |  Show IntroductionHide Introduction

Who Should Take Vitamin Supplements?

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
daily dietary intake level that is sufficient to meet the nutrient requirements of most healthy adults ...
Many patients ask their healthcare providers whether they should take vitamins. Since the last Medical Letter article on this subject, more data have become available on the benefits and risks of taking vitamins.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):101-3 |  Show IntroductionHide Introduction

Drugs for Open-Angle Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
as timolol 0.5% solution in patients with a baseline IOP of ...
Glaucoma is a progressive optic neuropathy associated with increased intraocular pressure (IOP; normal range 8-22 mm Hg), which is the only disease-related factor that can be modified. Topical drugs that lower IOP are the first line of treatment for open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8   doi:10.58347/tml.2025.1727a |  Show IntroductionHide Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
. Available at: www.cdc.gov/vaccines/ acip/meetings/downloads/min-archive/min-2018-02-508.pdf. Accessed ...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine...
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 |  Show IntroductionHide Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
(AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 ...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
4 RCT. 42nd Annual Meeting of The Obesity Society at ObesityWeek; San Antonio, TX; November 3–6 ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019  (Issue 1586)
in patients with a baseline IOP of ...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
of oral phenylephrine as a nasal decongestant. Nonprescription Drugs Advisory Committee meeting ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction